A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/?or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Active:	Yes
Cancer Type:	Metastases Solid Tumor	NCT ID:	NCT07492680
Trial Phases:	Phase II	Protocol IDs:	CA240-0005 (primary) 2025-524285-18 ( Other Identifier ) (OTHER: EU CTR U1111-1330-1428 ( Other Identifier ) (OTHER: WHO)
Eligibility:	, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	https://clinicaltrials.gov/study/NCT07492680

Summary

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.

Objectives

Part 1 will include parallel enrolment of tumor-specific dose-expansion cohorts evaluating BMS-986504 as monotherapy. Part 2 will include dose-escalation cohorts in which BMS-986504 is given in combination with other anticancer agents. Additional cohorts may be added based on emerging data.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.